Arabesque Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Arabesque Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-8,421	Closed	-$2.43M	–	125
2022 Q4	$2.43M	Sell	8,421 -32	-0.4%	-$9.75K	0.82%	59
2022 Q3	$2.45M	Buy	+8,453	New	+$2.43M	1.19%	16
2021 Q1	–	Sell	-3,576	Closed	-$845K	–	129
2020 Q4	$845K	Sell	3,576 -6,039	-63%	-$1.39M	0.25%	57
2020 Q3	$2.62M	Sell	9,615 -2,206	-19%	-$609K	2.35%	19
2020 Q2	$3.43M	Sell	11,821 -1,913	-14%	-$519K	2.32%	8
2020 Q1	$3.27M	Buy	+13,734	New	+$3.15M	6.76%	1

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arabesque Asset Management's VRTX Position: Q1 2023 in Review

Arabesque Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2023, closing a stake of 8,421 shares — an estimated $2.43M sold.

Arabesque Asset Management first reported a position in VRTX in Q1 2020 and held it in 6 quarters. The position peaked at $3.43M in Q2 2020. 1,208 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

Arabesque Asset Management reported no remaining Vertex Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Arabesque Asset Management sold 8,421 Vertex Pharmaceuticals shares in Q1 2023, an estimated $2.43M.
Arabesque Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 6 quarters.
Arabesque Asset Management's Vertex Pharmaceuticals position peaked at $3.43M in Q2 2020.
1,208 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on Arabesque Asset Management's 13F filing for Q1 2023.